In allergological practice, we often see patients with serum eosinophil counts above normal. These elevations are generally mild and are easily related to an atopic background. We also see patients requiring a differential diagnosis owing to eosinophilia of indeterminate origin. The present case seeks to alert clinicians to the need to investigate the etiology of casually identified eosinophilia, particularly with the purpose of diagnosing underlying disorders that are not clinically manifest at the time (eg, proliferative syndromes, parasitoses, drugs, autoimmune diseases) and could cause collateral damage owing to eosinophilic infiltration of various tissues if not adequately treated. In general, all cases of moderate to severe eosinophilia persisting for over 6 months should be monitored through laboratory tests and echocardiography, with administration of adequate corrective treatment, even cytoreductive medication [1] [2] [3] .
We present the case of a 28-year-old woman who consulted owing to the casual identification of marked eosinophilia (3000/µL, 40%) in a blood count requested by her gynecologist for the evaluation of an ovarian cyst that was casually detected during a routine annual ultrasound exploration. The blood count was repeated 1 week later, with a manual reading of the blood smear, and confirmed persistent eosinophilia of similar magnitude (2980/µL, 36.6%). The case history showed that the eosinophil counts had always been under 200/µL in previous years. The patient therefore consulted the allergology clinic, where a detailed history was taken, with assessment of the most common possible causes (especially atopic disease and parasitic infestation). She reported having had mild symptoms of nonseasonal rhinitis for several years and mild dyspepsia, with no malaise, altered bowel habit, weight loss, fever, or other signs or symptoms of systemic disease or abnormalities associated with infiltration of organs by eosinophils. The
The drugs most commonly associated with the induction of eosinophilia are ß-lactam antibiotics, tetracyclines, nonsteroidal antiinflammatory drugs, ranitidine, allopurinol, sulfasalazine, carbamazepine, cyclosporine, hydrochlorothiazide, and phenytoin [1] [2] [3] . The adverse reactions most frequently described in relation to lipid-lowering medications are gastrointestinal discomfort, myositis or rhabdomyolysis, neurological alterations, skin rash [5] , angioedema [6] , and pneumonitis [7] . Hampson et al [6] reported episodes of anaphylaxis (angioedema and hypotension) associated with eosinophilia following the administration of atorvastatin, probably involving an IgE-mediated mechanism. The prevalence of allergic sensitization to statins is estimated to be 0.1% [7, 8] .
A review of the literature shows the present report to be the first to describe a case of asymptomatic eosinophilia due to simvastatin therapy. Tang et al [9] reported a case of prolonged (4 months) eosinophilia in relation to atorvastatin use, with secondary eosinophilic infiltration of the intestinal tissues causing moderate abdominal pain. Both alterations disappeared after suspending treatment.
The way in which simvastatin caused peripheral eosinophilia in the case we report is not clear. According to Cozzani et al [10] , atorvastatin may have activated the STAT3 signaling pathway.
On the other hand, although the possibility of crossreactivity between the different statins has not been established, some of the patients tolerated statins (rosuvastatin) other than the drug implicated in the initial adverse reaction [9, 10] . In the case we report, fibrates will be prescribed if necessary. Initiation of rosuvastatin may be considered later, with close monitoring of the eosinophil count.
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patient had travelled to South America 18 months previously and had a dog at home. She received regular medication in the form of oral contraceptives, levothyroxine due to hypothyroidism (for the previous 6 years), and simvastatin prescribed by the endocrinologist 2 months previously because of hypercholesterolemia.
Complementary tests were requested mainly to rule out atopic disease, hematological disorders, autoimmune disease, liver disease, lung disease, and parasitic infestation capable of accounting for the eosinophilia. Possible implication of the ovarian cyst was also evaluated, and a differential diagnosis with hydatid cyst at an uncommon location was established. The studies included skin testing of common aeroallergens in our setting (ie, latex, lipid transfer protein, profilin, and Anisakis [with negative results, negative control saline solution, and histamine reaction of 7 mm]), full biochemical profile (liver and kidney function, iron metabolism), serum immunoglobulins, protein profile, antinuclear antibodies, and anti-DNA antibodies, Strongyloides and hydatidosis serology, urine sediment, serial stool parasite study, total IgE (75 kU/L), serum tryptase, chest x-rays, and abdominal ultrasound. Several biopsy specimens were obtained using esophagogastroscopy, and follow-up of the ovarian cyst with determination of levels of luteinizing hormone, folliclestimulating hormone, and various ovarian carcinomatosis markers was prescribed. All the results were within normal limits except for simple liver cysts that were not suggestive of hydatidosis. The ovarian cyst disappeared with the following menstrual period.
Furthermore, in order to rule out drug treatment as a causal factor of eosinophilia, simvastatin was suspended, and follow-up was based on serial blood counts and monitoring of cholesterol levels. The blood count obtained 2 weeks after drug suspension revealed a clear decrease in eosinophil count (430/µL, 8.9%), and, 2 weeks later, the count was seen to have returned to normal (180/µL, 4.8%), with no alteration of the concentration of cholesterol (187 mg/dL) or its fractions. The patient rejected the reintroduction of statin therapy to assess possible repetition of eosinophilia.
Many cases of mild eosinophilia (400-1500/µL) are casual findings and tend to resolve spontaneously. Nevertheless, it is considered essential to rule out a number of possible diseases such as allergic disorders with respiratory and/or cutaneous manifestations, drug allergies, parasitoses, cancer, adrenal gland insufficiency, connective tissue disease, and HIV infection. Likewise, possible eosinophilia of indeterminate origin should be contemplated in the case of moderate (1500-5000 µL) to severe eosinophilia (>5000 µL), with due evaluation and treatment [1] [2] [3] . The diagnosis therefore requires a detailed history and physical examination, with complementary laboratory tests (kidney and liver function), chest x-ray, abdominal ultrasound, parasitic and viral serology, immune activity studies, and the detection of autoantibodies according to the clinical suspicion in each case [1] [2] [3] . On the other hand, a number of case series involving prolonged follow-up periods have reported persistently asymptomatic eosinophilia (>1500 µL), such cases being regarded as benign disorders or hypereosinophilia of unknown significance [4] .
Systemic juvenile idiopathic arthritis (sJIA) is a polygenic autoinflammatory disease and the most common cause of arthritis in children and adolescents [1] . Macrophage activation syndrome is the most challenging adverse effect. IL-6 is involved in the pathophysiology of macrophage activation syndrome. Tocilizumab is a biologic agent approved for the treatment of rheumatoid arthritis (RA) in adults, polyarticular juvenile rheumatoid arthritis, and the systemic form of juvenile idiopathic arthritis in children. Tocilizumab blocks the IL-6 receptor in order to discontinue production of inflammation in the body. It is approved in Europe and the USA for the treatment of moderate to severe RA in adult patients who have responded inadequately or been intolerant to previous therapy with 1 or more diseasemodifying antirheumatic drugs or tumor necrosis factor inhibitors [2] . Anaphylactic adverse effects have been reported for tocilizumab, and incidence has been increasing over time [3] .
A 15-year-old boy presented 9 months ago with progressive pain in the neck, left knee, and back. He had concurrent fever and rash starting on the palms and spreading all over the body. Given the persistent fever, epistaxis, and bicytopenia, he was diagnosed with macrophage activation syndrome and underwent bone morrow aspiration. Hemophagocytosis was seen in 2 separate samples. Therefore, the patient was diagnosed as having JIA. As pulse methylprednisolone treatment was ineffective, tocilizumab was considered after treatment with intravenous immunoglobulin. The infusion was commenced at 600 mg every 2 weeks. After the second dose, the patient developed pruritus, maculopapular rash, angioedema, and dyspnea and was diagnosed with grade 2 anaphylaxis [4] . The tocilizumab infusion was stopped, and epinephrine (0.01 mg/kg) and pheniramine maleate (1 mg/kg) were administered. The treatment protocol was withdrawn for 2 weeks.
